Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Elevated HIF-1α expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy.
Matsunaga T, Imataki O, Torii E, Kameda T, Shide K, Shimoda H, Kamiunten A, Sekine M, Taniguchi Y, Yamamoto S, Hidaka T, Katayose K, Kubuki Y, Dobashi H, Bandoh S, Ohnishi H, Fukai F, Shimoda K. Matsunaga T, et al. Among authors: kamiunten a. Leuk Res. 2012 Jun;36(6):e122-4. doi: 10.1016/j.leukres.2012.02.028. Epub 2012 Mar 22. Leuk Res. 2012. PMID: 22444690 No abstract available.
TET2 is essential for survival and hematopoietic stem cell homeostasis.
Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A, Sekine M, Hidaka T, Katayose K, Kubuki Y, Yamamoto S, Miike T, Iwakiri H, Hasuike S, Nagata K, Marutsuka K, Iwama A, Matsuda T, Kitanaka A, Shimoda K. Shide K, et al. Among authors: kamiunten a. Leukemia. 2012 Oct;26(10):2216-23. doi: 10.1038/leu.2012.94. Epub 2012 Apr 3. Leukemia. 2012. PMID: 22469782
Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation.
Matsunaga T, Fukai F, Kameda T, Shide K, Shimoda H, Torii E, Kamiunten A, Sekine M, Yamamoto S, Hidaka T, Kubuki Y, Yokokura S, Uemura M, Matsuoka A, Waki F, Matsumoto K, Kanaji N, Ishii T, Imataki O, Dobashi H, Bandoh S, Shimoda K. Matsunaga T, et al. Among authors: kamiunten a. Ann Hematol. 2012 Oct;91(10):1633-43. doi: 10.1007/s00277-012-1498-y. Epub 2012 May 29. Ann Hematol. 2012. PMID: 22644786
Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan.
Matsunaga T, Yamashita K, Kubuki Y, Toyama T, Imataki O, Maeda K, Kawano N, Satou S, Kawano H, Ishizaki J, Yoshida S, Kameda T, Sasaki T, Sekine M, Kamiunten A, Taniguchi Y, Hidaka T, Katayose K, K-Shimoda H, Shide K, Yamamoto S, Moritake H, Nunoi H, Makino S, Kitanaka A, Matsuoka H, Shimoda K. Matsunaga T, et al. Among authors: kamiunten a. Int J Hematol. 2012 Sep;96(3):342-9. doi: 10.1007/s12185-012-1146-2. Epub 2012 Jul 24. Int J Hematol. 2012. PMID: 22825970
Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.
Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, Hidaka T, Kubuki Y, Shimoda H, Marutsuka K, Sashida G, Aoyama K, Yoshimitsu M, Harada T, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K. Kameda T, et al. Among authors: kamiunten a. Blood. 2015 Jan 8;125(2):304-15. doi: 10.1182/blood-2014-04-555508. Epub 2014 Nov 13. Blood. 2015. PMID: 25395421 Free article.
Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms.
Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Hidaka T, Kubuki Y, Sashida G, Aoyama K, Yoshimitsu M, Abe H, Miike T, Iwakiri H, Tahara Y, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K. Kameda T, et al. Among authors: kamiunten a. Genom Data. 2015 Apr 9;4:102-8. doi: 10.1016/j.gdata.2015.04.002. eCollection 2015 Jun. Genom Data. 2015. PMID: 26484191 Free PMC article.
TET2 Mutation in Adult T-Cell Leukemia/Lymphoma.
Shimoda K, Shide K, Kameda T, Hidaka T, Kubuki Y, Kamiunten A, Sekine M, Akizuki K, Shimoda H, Yamaji T, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Kitanaka A. Shimoda K, et al. Among authors: kamiunten a. J Clin Exp Hematop. 2015;55(3):145-9. doi: 10.3960/jslrt.55.145. J Clin Exp Hematop. 2015. PMID: 26763362 Free article.
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
Shide K, Kameda T, Yamaji T, Sekine M, Inada N, Kamiunten A, Akizuki K, Nakamura K, Hidaka T, Kubuki Y, Shimoda H, Kitanaka A, Honda A, Sawaguchi A, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hasuike S, Yamamoto S, Nagata K, Shimoda K. Shide K, et al. Among authors: kamiunten a. Leukemia. 2017 May;31(5):1136-1144. doi: 10.1038/leu.2016.308. Epub 2016 Nov 3. Leukemia. 2017. PMID: 27807369 Free PMC article.
Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.
Kubuki Y, Shide K, Kameda T, Yamaji T, Sekine M, Kamiunten A, Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hashimoto K, Yamamoto S, Hasuike S, Hidaka T, Nagata K, Kitanaka A, Shimoda K. Kubuki Y, et al. Among authors: kamiunten a. Ann Lab Med. 2017 Mar;37(2):159-161. doi: 10.3343/alm.2017.37.2.159. Ann Lab Med. 2017. PMID: 28029004 Free PMC article. No abstract available.
33 results